For Atrial Fibrillation, DOACs Outperform Warfarin in Patients with Reduced Kidney Function

References

1. 1.↵
   1. Harrington J,
   2. Carnicelli AP,
   3. Hua K,
   4. et al

   . Direct oral anticoagulants versus warfarin across the spectrum of kidney function: patient-level network meta-analyses from COMBINE AF. Circulation 2023;147:1748–57.

   OpenUrlPubMed
2. 2.↵
   1. Kim SM,
   2. Jeong Y,
   3. Kim YL,
   4. et al

   . Association of chronic kidney disease with atrial fibrillation in the general adult population: a nationwide population-based study. J Am Heart Assoc 2023;12:e028496.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Kumar S,
   2. Lim E,
   3. Covic A,
   4. et al

   . Anticoagulation in concomitant chronic kidney disease and atrial fibrillation: JACC review topic of the week. J Am Coll Cardiol 2019;74:2204–15.

   OpenUrlFREE Full Text
4. 4.↵
   1. Joglar JA,
   2. Chung MK,
   3. Armbruster AL

   , Peer Review Committee Memberset al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2023;149:e1–e156.

   OpenUrlPubMed
5. 5.↵
   1. Kimachi M,
   2. Furukawa TA,
   3. Kimachi K,
   4. Goto Y,
   5. Fukuma S,
   6. Fukuhara S

   . Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease. Cochrane Database Syst Rev 2017;11:CD011373.

   OpenUrlCrossRefPubMed
6. 6.↵
   The Priority Updates from the Research Literature (PURLs) methodology. Available at: https://journals.lww.com/ebp/Documents/PURLs%20Methods%20AC.pdf.